Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Evolution of our understanding of the aVR sign.

Gibbs MA, Leedekerken JB, Littmann L.

J Electrocardiol. 2019 Sep - Oct;56:121-124. doi: 10.1016/j.jelectrocard.2019.07.014. Epub 2019 Aug 1. Review.

PMID:
31401390
2.

Initial evaluation and management of wide-complex tachycardia: A simplified and practical approach.

Littmann L, Olson EG, Gibbs MA.

Am J Emerg Med. 2019 Jul;37(7):1340-1345. doi: 10.1016/j.ajem.2019.04.027. Epub 2019 Apr 12. Review.

PMID:
31027937
3.

More on the pacemaker ECG in severe hyperkalemia.

Littmann L, Gibbs MA.

J Electrocardiol. 2018 Nov - Dec;51(6):1156-1157. doi: 10.1016/j.jelectrocard.2018.09.007. Epub 2018 Sep 11. No abstract available.

PMID:
30224191
4.

Electrocardiographic manifestations of severe hyperkalemia.

Littmann L, Gibbs MA.

J Electrocardiol. 2018 Sep - Oct;51(5):814-817. doi: 10.1016/j.jelectrocard.2018.06.018. Epub 2018 Jul 4. Review.

PMID:
30177318
5.

Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor.

Kasichayanula S, Grover A, Emery MG, Gibbs MA, Somaratne R, Wasserman SM, Gibbs JP.

Clin Pharmacokinet. 2018 Jul;57(7):769-779. doi: 10.1007/s40262-017-0620-7. Review.

6.

Meal Timing Regulates the Human Circadian System.

Wehrens SMT, Christou S, Isherwood C, Middleton B, Gibbs MA, Archer SN, Skene DJ, Johnston JD.

Curr Biol. 2017 Jun 19;27(12):1768-1775.e3. doi: 10.1016/j.cub.2017.04.059. Epub 2017 Jun 1.

7.

Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).

Gibbs JP, Doshi S, Kuchimanchi M, Grover A, Emery MG, Dodds MG, Gibbs MA, Somaratne R, Wasserman SM, Blom D.

J Clin Pharmacol. 2017 May;57(5):616-626. doi: 10.1002/jcph.840. Epub 2016 Nov 15.

8.

Computer technology for self-management: a scoping review.

Jacelon CS, Gibbs MA, Ridgway JV.

J Clin Nurs. 2016 May;25(9-10):1179-92. doi: 10.1111/jocn.13221. Epub 2016 Mar 18. Review.

PMID:
26990364
9.

Respiratory Emergencies.

Vissers RJ, Gibbs MA.

Emerg Med Clin North Am. 2016 Feb;34(1):xiii-xiv. doi: 10.1016/j.emc.2015.10.002. No abstract available.

PMID:
26614248
10.

Impact of common crystalloid solutions on resuscitation markers following Class I hemorrhage: A randomized control trial.

Ross SW, Christmas AB, Fischer PE, Holway H, Walters AL, Seymour R, Gibbs MA, Heniford BT, Sing RF.

J Trauma Acute Care Surg. 2015 Nov;79(5):732-40. doi: 10.1097/TA.0000000000000833.

PMID:
26496098
11.

Femur fractures should not be considered distracting injuries for cervical spine assessment.

Dahlquist RT, Fischer PE, Desai H, Rogers A, Christmas AB, Gibbs MA, Sing RF.

Am J Emerg Med. 2015 Dec;33(12):1750-4. doi: 10.1016/j.ajem.2015.08.009. Epub 2015 Aug 10.

PMID:
26346048
12.

Ignorance is not bliss: Statistical power is not probability of trial success.

Zierhut ML, Bycott P, Gibbs MA, Smith BP, Vicini P.

Clin Pharmacol Ther. 2016 Apr;99(4):356-9. doi: 10.1002/cpt.257. Epub 2015 Oct 23.

PMID:
26331445
13.

Model-based assessment of dosing strategies in children for monoclonal antibodies exhibiting target-mediated drug disposition.

Zheng S, Gaitonde P, Andrew MA, Gibbs MA, Lesko LJ, Schmidt S.

CPT Pharmacometrics Syst Pharmacol. 2014 Oct 1;3:e138. doi: 10.1038/psp.2014.38.

14.

A semi-mechanistic model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in a first-in-human single ascending dose study.

Salinger DH, Endres CJ, Martin DA, Gibbs MA.

Clin Pharmacol Drug Dev. 2014 Jul;3(4):276-83. doi: 10.1002/cpdd.103. Epub 2014 Feb 18.

PMID:
27128833
15.

Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studies.

Endres CJ, Salinger DH, Köck K, Gastonguay MR, Martin DA, Klekotka P, Nirula A, Gibbs MA.

J Clin Pharmacol. 2014 Nov;54(11):1230-8. doi: 10.1002/jcph.334. Epub 2014 May 27.

PMID:
24846347
16.

A model-based meta-analysis of monoclonal antibody pharmacokinetics to guide optimal first-in-human study design.

Davda JP, Dodds MG, Gibbs MA, Wisdom W, Gibbs J.

MAbs. 2014 Jul-Aug;6(4):1094-102. doi: 10.4161/mabs.29095. Epub 2014 May 16.

17.

Greater seasonal cycling of 25-hydroxyvitamin D is associated with increased parathyroid hormone and bone resorption.

Darling AL, Hart KH, Gibbs MA, Gossiel F, Kantermann T, Horton K, Johnsen S, Berry JL, Skene DJ, Eastell R, Vieth R, Lanham-New SA.

Osteoporos Int. 2014 Mar;25(3):933-41. doi: 10.1007/s00198-013-2493-4. Epub 2013 Aug 28.

PMID:
23982802
18.

Clinical Trial Simulation to Inform Phase 2: Comparison of Concentrated vs. Distributed First-in-Patient Study Designs in Psoriasis.

Dodds MG, Salinger DH, Mandema J, Gibbs JP, Gibbs MA.

CPT Pharmacometrics Syst Pharmacol. 2013 Jul 24;2:e58. doi: 10.1038/psp.2013.32.

19.

Managing blunt trauma in patients receiving dabigatran etexilate: case study and review of the literature.

Croft PE, Cabral KP, Strout TD, Baumann MR, Gibbs MA, Delaney MC.

J Emerg Nurs. 2013 May;39(3):302-8. doi: 10.1016/j.jen.2013.01.016. Epub 2013 Mar 28. Review. No abstract available.

PMID:
23541336
20.

Adaptations in tibial cortical thickness and total volumetric bone density in postmenopausal South Asian women with small bone size.

Darling AL, Hakim OA, Horton K, Gibbs MA, Cui L, Berry JL, Lanham-New SA, Hart KH.

Bone. 2013 Jul;55(1):36-43. doi: 10.1016/j.bone.2013.03.006. Epub 2013 Mar 24.

PMID:
23531785
21.

Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.

Gibbs JP, Fredrickson J, Barbee T, Correa I, Smith B, Lin SL, Gibbs MA.

J Clin Pharmacol. 2012 Oct;52(10):1494-505. Epub 2011 Dec 12.

PMID:
22162539
22.

A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis.

Mandema JW, Salinger DH, Baumgartner SW, Gibbs MA.

Clin Pharmacol Ther. 2011 Dec;90(6):828-35. doi: 10.1038/clpt.2011.256. Epub 2011 Nov 2.

PMID:
22048227
23.

Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction.

Dong JQ, Salinger DH, Endres CJ, Gibbs JP, Hsu CP, Stouch BJ, Hurh E, Gibbs MA.

Clin Pharmacokinet. 2011 Feb;50(2):131-42. doi: 10.2165/11537430-000000000-00000.

PMID:
21241072
24.

Population pharmacokinetic/pharmacodynamic model of subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity after oral administration of AMG 221, a selective 11β-HSD1 inhibitor.

Gibbs JP, Emery MG, McCaffery I, Smith B, Gibbs MA, Akrami A, Rossi J, Paweletz K, Gastonguay MR, Bautista E, Wang M, Perfetti R, Daniels O.

J Clin Pharmacol. 2011 Jun;51(6):830-41. doi: 10.1177/0091270010374470. Epub 2010 Jul 27.

PMID:
20663992
25.

The high-risk airway.

Vissers RJ, Gibbs MA.

Emerg Med Clin North Am. 2010 Feb;28(1):203-17, ix-x. doi: 10.1016/j.emc.2009.10.004.

PMID:
19945607
26.

Evaluation of structural models to describe the effect of placebo upon the time course of major depressive disorder.

Shang EY, Gibbs MA, Landen JW, Krams M, Russell T, Denman NG, Mould DR.

J Pharmacokinet Pharmacodyn. 2009 Feb;36(1):63-80. doi: 10.1007/s10928-009-9110-3. Epub 2009 Feb 10.

PMID:
19205853
27.

Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures.

Venkatakrishnan K, Tseng E, Nelson FR, Rollema H, French JL, Kaplan IV, Horner WE, Gibbs MA.

Drug Metab Dispos. 2007 Aug;35(8):1341-9. Epub 2007 Apr 30.

PMID:
17470526
28.
29.

Peripheral nerve blocks of the hand.

Dillon D, Gibbs MA, Baby C.

Acad Emerg Med. 2007 Jan;14(1):14-5. No abstract available.

30.

CYP3A5 polymorphism and alprazolam pharmacokinetics/pharmacodynamics.

Venkatakrishnan K, Gibbs MA.

Clin Pharmacol Ther. 2006 Dec;80(6):719-20; author reply 720. No abstract available.

PMID:
17178274
31.

Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers.

Faessel HM, Gibbs MA, Clark DJ, Rohrbacher K, Stolar M, Burstein AH.

J Clin Pharmacol. 2006 Dec;46(12):1439-48.

PMID:
17101743
32.

Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.

Taylor TJ, Diringer K, Russell T, Venkatakrishnan K, Wilner K, Crownover PH, Benincosa LJ, Gibbs MA.

Clin Pharmacokinet. 2006;45(10):989-1001.

PMID:
16984212
33.

Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers.

Faessel HM, Smith BJ, Gibbs MA, Gobey JS, Clark DJ, Burstein AH.

J Clin Pharmacol. 2006 Sep;46(9):991-8.

PMID:
16920893
34.

The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model.

Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, Chen C, Chen X, Choo E, Cianfrogna J, Cox LM, Gibbs JP, Gibbs MA, Hatch H, Hop CE, Kasman IN, Laperle J, Liu J, Liu X, Logman M, Maclin D, Nedza FM, Nelson F, Olson E, Rahematpura S, Raunig D, Rogers S, Schmidt K, Spracklin DK, Szewc M, Troutman M, Tseng E, Tu M, Van Deusen JW, Venkatakrishnan K, Walens G, Wang EQ, Wong D, Yasgar AS, Zhang C.

Drug Metab Dispos. 2005 Jan;33(1):165-74. Epub 2004 Oct 22.

PMID:
15502009
35.
36.

Development of the lateral line system in the shovelnose sturgeon.

Gibbs MA, Northcutt RG.

Brain Behav Evol. 2004;64(2):70-84. Epub 2004 Jun 15.

PMID:
15205543
37.

Retinoic acid repatterns axolotl lateral line receptors.

Gibbs MA, Northcutt RG.

Int J Dev Biol. 2004 Feb;48(1):63-6.

38.
39.

Factors affecting the clinical development of cytochrome p450 3A substrates.

Gibbs MA, Hosea NA.

Clin Pharmacokinet. 2003;42(11):969-84. Review.

PMID:
12908853
40.
41.

Guidelines for emergency tracheal intubation immediately after traumatic injury.

Dunham CM, Barraco RD, Clark DE, Daley BJ, Davis FE 3rd, Gibbs MA, Knuth T, Letarte PB, Luchette FA, Omert L, Weireter LJ, Wiles CE 3rd; EAST Practice Management Guidelines Work Group.

J Trauma. 2003 Jul;55(1):162-79. Review. No abstract available.

PMID:
12855901
42.

Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors.

Tran TH, Von Moltke LL, Venkatakrishnan K, Granda BW, Gibbs MA, Obach RS, Harmatz JS, Greenblatt DJ.

Drug Metab Dispos. 2002 Dec;30(12):1441-5.

PMID:
12433817
43.

Antihypertensive medications and renal disease.

Andrews L, Gibbs MA.

Nephrol Nurs J. 2002 Aug;29(4):379-82. Review.

PMID:
12224374
44.

The "swallowed" endotracheal tube.

Sing RF, Huynh TT, Gibbs MA, Perron AD.

Am J Emerg Med. 2001 Nov;19(7):606-7. No abstract available.

PMID:
11699017
45.

Emergency department management of patients with seizures: a multicenter study.

Huff JS, Morris DL, Kothari RU, Gibbs MA; Emergency Medicine Seizure Study Group.

Acad Emerg Med. 2001 Jun;8(6):622-8.

46.

Ascorbic acid use in hyporesponders to Epoetin alfa.

Gibbs MA.

Nephrol Nurs J. 2000 Aug;27(4):413-5.

PMID:
11276634
47.

State of the art: therapeutic controversies in severe acute asthma.

Gibbs MA, Camargo CA Jr, Rowe BH, Silverman RA.

Acad Emerg Med. 2000 Jul;7(7):800-15. Review.

48.

Value of point-of-care blood testing in emergent trauma management.

Asimos AW, Gibbs MA, Marx JA, Jacobs DG, Erwin RJ, Norton HJ, Thomason M.

J Trauma. 2000 Jun;48(6):1101-8.

PMID:
10866258
49.

Persistent inhibition of CYP3A4 by ketoconazole in modified Caco-2 cells.

Gibbs MA, Baillie MT, Shen DD, Kunze KL, Thummel KE.

Pharm Res. 2000 Mar;17(3):299-305.

PMID:
10801218
50.

Hydroxyurea in the treatment of HIV-1.

Gibbs MA, Sorensen SJ.

Ann Pharmacother. 2000 Jan;34(1):89-93. Review.

PMID:
10669190

Supplemental Content

Loading ...
Support Center